摘要
为探究血清肿瘤标志物联合检验诊断结直肠癌的价值,选取2017-2018年在我院治疗的67例结直肠癌患者为观察组,并以同期健康体检者67名为对照组,观察2组癌胚抗原(CEA)、糖类抗原(CA19-9、CA72-4)、细胞角蛋白19的可溶性片段(CYFRA211)的表达水平、不同分期血清肿瘤标志物水平以及检测灵敏度与特异性。结果显示,经检测后,观察组患者的CEA、CA19-9、CA72-4、CYFRA211水平显著高于对照组(P <0.05)。晚期结直肠癌患者CEA、CA19-9、CA72-4以及CYFRA211检测水平均高于早期,比较差异有统计学意义(P <0.05)。观察组患者CEA、CA19-9、CA72-4以及CYFRA211单一敏感性分别为66.98%、68.54%、66.21%和68.13%,联合检测敏感性为86.98%,单一检测特异性分别为86.98%、83.56%、79.98%和84.56%,联合检测特异性为89.56%,比较差异有统计学意义(P <0.05)。结果表明,血清肿瘤标志物联合检测可提高结直肠癌的诊断率,有助于早期与晚期的鉴别,为临床提供重要的治疗依据。
This study was to investigate the value of serum tumor marker combined laboratory exam.in the diagnosis of colorectal cancer,enrolled 67 patietns with colorectal cancer treated in author’s hospital(2017-2018 yr.)as observation group,at the same time,67 physical examinees as control group;then,observed and compared both groups’ levels of CEA,CA19-9,CA72-4,and CYFRA 211;and the levels of serum tumor markers at different stages,as well as the sensitivity and specificity of detection.As results,the levels of CEA,CA19-9,CA72-4,and CYFRA 211 in observation group were significantly higher than that in control group(P <0.05);in late patients above levels were higher than in early patients(P <0.05);in observation groups’ patients the sensitivity of single CEA,CA19-9,CA72-4,and CYFRA 211 detection was respectively 66.98%,68.54%,66.21% and 68.13%;while the sensitivity of their combination detection was86.98%,the difference was significant(P <0.05);the specificity of single one’s detection was respectively86.98%,83.56%,79.89%and 84.56%,while combination detections’ specificity was 89.56%,the difference was significant(P <0.05).Results show that serum tumor marker combined laboratory exam.can enhance diagnostic rate of colorectal cancer,and is helpful to differentiate early tumor and late one,thus provide important treatment basis clinically.
作者
杜彪
DU Biao(Dept,of Laboratory and Transfusion,No.989 Hospital of PLA,Luoyang,Henan 471000)
出处
《中国肛肠病杂志》
2021年第1期4-6,共3页
Chinese Journal of Coloproctology
关键词
结直肠癌
血清
肿瘤标志物
诊断
Colorectal cancer
Serum
Tumor marker
Diagnosis